REGN

Regeneron Pharmaceuticals
D

REGN

Arincen73/100B
904.38
USD
1.56
(0.17%)
Pre Open·910.20USD+5.82(+0.64%)
Last updated: · Delayed 15 min
Fair value814.64Plus+11%346Price 904.381,431
Q4 FY2026 · Earnings report
EPS estimate 25.39Revenue estimate 5.85B
OverviewFinancialsForecastEarningsDividendsCompany

Regeneron Pharmaceuticals cash on hand 1990–2026

Regeneron Pharmaceuticals had 9.30B USD in cash and short-term investments on 30 September 2026, up 10.2% on a year before. At the end of fiscal year 2025 it had 8.61B USD.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Cash on hand

Growth

Fiscal yearPeriod endingCash on handGrowthTotal debtNet cash
Latest quarter30 Sept 20269.30B+10.16%2.71B6.59B
FY202531 Dec 20258.61B-4.52%2.71B5.90B
FY202431 Dec 20249.01B-16.90%2.70B6.31B
FY202331 Dec 202310.84B+40.07%2.70B8.14B
FY202231 Dec 20227.74B+35.96%2.70B5.04B
FY202131 Dec 20215.69B+58.76%2.70B3.00B
FY202031 Dec 20203.59B+11.60%2.70B891.30M
FY201931 Dec 20193.21B+14.39%713.90M2.50B
FY201831 Dec 20182.81B+99.34%708.50M2.10B
FY201731 Dec 20171.41B+35.71%703.45M706.13M
FY201631 Dec 20161.04B-0.63%481.13M557.56M
FY201531 Dec 20151.05B+16.07%375.51M669.71M
FY201431 Dec 2014900.48M+29.76%459.06M441.42M
FY201331 Dec 2013693.98M+125.25%505.51M188.47M
FY201231 Dec 2012308.10M-41.53%457.33M-149.23M
FY201131 Dec 2011526.94M+111.31%435.53M91.41M
FY201031 Dec 2010249.37M-26.94%160.03M89.34M
FY200931 Dec 2009341.33M-28.10%109.02M232.31M
FY200831 Dec 2008474.75M-38.06%5.09M469.66M
FY200731 Dec 2007766.46M+66.88%202.29M564.17M
FY200631 Dec 2006459.28M+53.84%200.00M259.28M
FY200531 Dec 2005298.55M+0.87%200.00M98.55M
FY200431 Dec 2004295.98M+0.75%200.00M95.98M
FY200331 Dec 2003293.77M+11.16%213.82M79.96M
FY200231 Dec 2002264.27M-31.37%200.15M64.12M
FY200131 Dec 2001385.08M+227.41%200.58M184.50M
FY200031 Dec 2000117.61M+77.66%2.68M114.93M
FY199931 Dec 199966.20M+234.34%4.10M62.10M
FY199831 Dec 199819.80M-31.49%4.20M15.60M
FY199731 Dec 199728.90M-16.23%5.60M23.30M
FY199631 Dec 199634.50M+5.50%8.70M25.80M
FY199531 Dec 199532.70M+38.56%9.50M23.20M
FY199431 Dec 199423.60M+88.80%12.30M11.30M
FY199331 Dec 199312.50M-23.78%7.50M5.00M
FY199231 Dec 199216.40M-37.40%6.80M9.60M
FY199131 Dec 199126.20M+20.18%2.80M23.40M
FY199031 Dec 199021.80M—0.0021.80M

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Stock buybacks,Balance sheet

Common questions about Regeneron Pharmaceuticals's cash

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.